-
Supporting SurvivorsPanel of experts discuss survivorship challenges and potential areas for study.
by Marci A. Landsmann
-
A New Type of Drug ApprovalAt the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors' molecular characteristics, not to their tissues of origin.
by Kate Yandell
-
Artificial Intelligence Characterizes CancerAt the AACR Annual Meeting 2018, researchers at Google compared the speed and accuracy of human pathologists and computer algorithms in diagnosing and grading cancer.
by Kevin McLaughlin
-
Non–Small Cell Lung Cancer Takes Center StageA trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non-small cell lung cancer treatment.
by Brad Jones
-
Cancer Researchers Offer Reasons for OptimismCancer researchers and patient advocates spoke about progress against cancer at a public education forum sponsored by the American Association for Cancer Research.
by Kevin McLaughlin
-
Pembrolizumab Shows Further Promise for MelanomaIn a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.
by Brad Jones
-
The Evolving Role of Patient AdvocacyAACR’s Scientist↔Survivor Program marks a milestone as patient advocates continue to shape research and policy.
by Marci A. Landsmann
-
An Advocate’s Guide to Attending Scientific MeetingsTwo graduates of the AACR Scientist↔Survivor Program share tips for getting the most out of large scientific conferences.
by Bob Riter and Carole Baas
-
AACR Scientist↔Survivor Program: The Patient PerspectiveIn a sea of p-values and distribution curves, patient advocates and survivors at a scientific gathering remind researchers who is behind the numbers.
by Marci A. Landsmann
-
Immunotherapy CombinationsResearchers are combining immunotherapies with each other and with other treatments in hopes that a larger proportion of patients will have long-term benefits.
by Kate Yandell
Scientists present data on the risks of immune checkpoint inhibitors so more patients can tap into the treatment.
by Marci A. Landsmann
Tissue and Liquid Biopsy for Targeted TherapyTailored treatments led to better outcomes than standard of care when biomarker results from liquid biopsy and tumor tissue aligned.
by Eric Fitzsimmons
Cancer Vaccines Show Promise in Early TrialsWhile mRNA vaccines offer a personalized approach to triggering an immune response, peptide vaccines could be a one-size-fits-all treatment. Researchers are exploring both options.
by Thomas Celona
Declining Breast Cancer Mortality in Younger WomenU.S. breast cancer deaths declined for women ages 20 to 49, which researchers credit to wider screening and better treatment.
by Kevin McLaughlin
-
Inaugural AACR IO Conference Kicks Off With Celebration of Immune CheckpointsImmune checkpoint icons James Allison and Arlene Sharpe shared their journeys and a look ahead on the opening night of the inaugural AACR IO conference.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
